Oxford BioMedica Announces Lentiviral Vector Development and Manufacturing Collaboration

03-May-2013 - United Kingdom

Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology. 

Under the terms of the agreement, Oxford BioMedica will also provide certain process development services and expects to receive between £2.5 million and £4 million from Novartis over the next 12 months. 

Oxford BioMedica will be responsible for manufacturing several batches of a lentiviral vector encoding CTL019 technology.  This vector will be used to transduce patients’ immune cells (T-cells) in an ex vivo process before they are re-infused into patients.  CTL019 targets a protein called CD19 that is associated with a number of B-cell malignancies including chronic lymphocytic leukemia, B-cell acute lymphocytic leukaemia and diffuse large B-cell lymphoma.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...